Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Olivier Le Moal Shares of Amicus Therapeutics (NASDAQ:FOLD) are up modestly since my September 2023 update where I argued that the limited label of Pombiliti+Opfolda may not matter for the product combination's uptake because it would have been used like the label says anyway. And while there are no real pipeline updates to look forward to, the company may attract a different kind of investor base going forward - investors predominantly focused on revenue and earnings momentum. Amicus should start deliverin ...